Relative expression (fold-change) of immune genes in LPS-stimulated peritoneal macrophages. by Chaiwat Monmai (6377270)

Relative expression (fold-change) of immune genes in mitogen-stimulated splenic lymphocytes. by Chaiwat Monmai (6377270)

Average packets rate. by Longyan Ran (18452261)

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

Screening of either Higher Binding Affinity or Non-affinity scFv against Wild-type or Beta SARS-CoV-2. by Ye Yang (297214)

Illustrations of the SeqFold2D network and the Stralign dataset. by Xiangyun Qiu (316117)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Effect of Safr and Cands on the gene expression level of monoamine oxidase (MAO-A, fold change) and (MAO-B, fold change) as well as the activities of monoamine oxidase (MAO, μM 4-H... by Nagwa Ibrahim Shehata (17319689)

Clinical characteristics of patients in the increased-, stable-, and decreased-RPR groups. by Kazuhiko Ikeuchi (9234268)

Subjects:

CCS1477 decreases phosphorylated ATR (pATR) and phosphorylated ATM (pATM). by Changkun Hu (12077989)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Settling time for changes in the median of the Folded Normal distribution. by Ariel Burman (20329776)

Fold change in EC₅₀ in all polyene resistant lines of <i>Leishmania spp</i>. by Edubiel A. Alpizar-Sosa (13848145)

“…<i>mexicana</i> in DM and E) AmBR-<i>L</i>. <i>infantum</i> in HOMEM. Values higher and lower than 1, indicate a decrease and rise in susceptibility relative to the parental line, respectively. …”

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

Taste sensilla in the wing and RNA-seq screen of control and <i>Poxn</i> wings. by Zhe He (508742)

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

GO analysis of stage-salient genes in the order of decreasing significance (i.e, increasing p–value). by Sangeetha Muthamilselvan (8966006)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Description of the cohort (N = 118 patients). by Bastien Le Floc’h (14773916)

“…An HLA-G plasma level ≤ 50 ng/ml on day 8 after LT was significantly associated with a higher rejection risk. …”